Immunotyping lymph nodes in immune-mediated inflammatory diseases

Immunotyping lymph nodes in immune-mediated inflammatory diseases (IMIDs): lymph node cellular and molecular biomarkers in IMIDs - Immunotyping lymph nodes in immune-mediated inflammatory diseases (IMIDs)

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON55414

Enrollment

750

Registered

2015-02-04

Start date

2018-05-23

Completion date

Unknown

Last updated

2026-04-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

chronic inflammatory diseases, IMID chronic inflammatory diseases

Interventions

nvt

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: IMID patients patients at risk of developing IMID first degree relatives of IMID patients healthy controls

Exclusion criteria

Exclusion criteria: patients unable to give informed consent

Design outcomes

Primary

Measure	Time frame
Differences in lymph node cellular composition and functional aspects in patients with established IMIDs, pre-clinical patients eventually developing IMIDs compared to pre-clinical patients that do not develop IMIDs, and of lymph nodes of first degree relatives compared to patients with IMIDs, all compared to lymph node tissue of healthy controls. Additionally, differences in cellular composition and functional aspects between lymph nodes and synovium/MRI in patients with established IMIDs or pre-clinical patients at risk of developing IMIDs (optional).	—

Measure

Time frame

Differences in lymph node cellular composition and functional aspects in patients with established IMIDs, pre-clinical patients eventually developing IMIDs compared to pre-clinical patients that do not develop IMIDs, and of lymph nodes of first degree relatives compared to patients with IMIDs, all compared to lymph node tissue of healthy controls. Additionally, differences in cellular composition and functional aspects between lymph nodes and synovium/MRI in patients with established IMIDs or pre-clinical patients at risk of developing IMIDs (optional).

—

Countries

Netherlands

Contacts

Public ContactS.W. Tas

Amsterdam UMC

s.w.tas@amsterdamumc.nl020-5667765

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP) · Data processed: May 1, 2026